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Abstract
Stem cell (SC) lines that capture the genetics of disease susceptibility provide new research tools. To assess the utility of
mouse central nervous system (CNS) SC-containing neurosphere cultures for studying heritable neurodegenerative disease,
we compared neurosphere cultures from transgenic mice that express human tau with the P301L familial frontotemporal
dementia (FTD) mutation, rTg(tauP301L)4510, with those expressing comparable levels of wild type human tau,
rTg(tauwt)21221. rTg(tauP301L)4510 mice express the human tauP301L variant in their forebrains and display cellular,
histological, biochemical and behavioral abnormalities similar to those in human FTD, including age-dependent differences
in tau phosphorylation that distinguish them from rTg(tauwt)21221 mice. We compared FTD-hallmark tau phosphorylation
in neurospheres from rTg(tauP301L)4510 mice and from rTg(tauwt)21221 mice. The tau genotype-specific phosphorylation
patterns in neurospheres mimicked those seen in mice, validating use of neurosphere cultures as models for studying tau
phosphorylation. Genotype-specific tau phosphorylation was observed in 35 independent cell lines from individual fetuses;
tau in rTg(tauP301L)4510 cultures was hypophosphorylated in comparison with rTg(tauwt)21221 as was seen in young adult
mice. In addition, there were fewer human tau-expressing cells in rTg(tauP301L)4510 than in rTg(tauwt)21221 cultures.
Following differentiation, neuronal filopodia-spine density was slightly greater in rTg(tauP301L)4510 than rTg(tauwt)21221
and control cultures. Together with the recapitulation of genotype-specific phosphorylation patterns, the observation that
neurosphere lines maintained their cell line-specific-differences and retained SC characteristics over several passages
supports the utility of SC cultures as surrogates for analysis of cellular disease mechanisms.
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Introduction
The ability to generate human embryonic stem cell lines by
somatic cell nuclear transfer [1] or to produce induced pluripotent
stem cells by reprogramming [2] provides the opportunity to
capture the genetics of diseased patients. The availability of
patient-specific SC lines offers the possibility of transplantation for
cell replacement or the delivery of therapeutic agents, and patient-
tailored drug therapy. Use of disease-specific SC lines to dissect
cellular disease processes is a burgeoning field yielding promising
results [3–16].
While our goals are to develop and validate approaches that can
be applied to patient-specific cell lines, mouse models offer
important advantages for experimental analysis. Each human
patient is unique, but members of inbred mouse strains are
genetically homogeneous, allowing discrimination of variation that
may be inherent to SC isolation from genetic effects. Mouse
models also allow tracking of the subtle biochemical, histological,
and behavioral changes that occur long before clinical signs
appear. By exploiting SC lines from well-characterized mouse
models, we hope to relate cell culture phenotypes to pre-clinical
pathogenic events.
Frontotemporal dementia (FTD) is a neurodegenerative disor-
der in which aggregates comprised of microtubule associated
protein tau (MAPT) form in neurons. FTD, like other tauopathies,
including Alzheimer’s disease, is characterized by tau phosphor-
ylation and aggregation events associated with neuronal death and
dementia. Transgenic mouse lines expressing human MAPT with
a proline to leucine mutation at amino acid 301 (P301L)
recapitulate aspects of familial FTD [17–20]. Ashe and colleagues
[19,20] developed a regulatable bigenic transgenic line
rTg(tauP301L)4510 (hereafter, rTg(tauP301L) is used to indicate
rTg(tauP301L)4510) in which MAPT transgene expression is largely
restricted to forebrain cells to avoid early spinal cord pathology
that develops in mice with prion protein promoter driven mutant
tau [18]. MAPT transgene expression can be suppressed with
doxycycline.
Here we report the isolation and characterization of neuro-
sphere lines from rTg(tauP301L) mice and from recently created
transgenic mice that express comparable levels of human tauwt,
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tion of neurospheres is a well-established technique and these
multi-cellular aggregates consist of CNS-SCs, lineage-committed,
and differentiated cells [22–25]. The effects of genetics on cell
proliferation, differentiation, and mature cell types can be assessed
in neurosphere cultures [22,23]. We evaluated the effects of the
P301L mutation on tau phosphorylation in mice and in SC lines
derived from them. Neurospheres recapitulated the genotype-
specific differences in tau phosphorylation seen in mice, and we
found genotype-dependent differences in the fraction of transgene
expressing cells, the level of phosphorylation, and in filopodia-
spine densities.
Materials and Methods
Mice
rTg(tauP301L) and rTg(tauwt) mice, along with similar lines
described in Results, were generated using a bigenic system of
responder and activator transgenes. Tg(tauP301L) and Tg(tauwt)
mice (designated TRE-tauP301L- and TRE-tauwt) carry their
corresponding tetO-tau responsive element transgenes and were
produced and maintained on the FVB/NCr background [19,21].
Tg(CK-tTA) mice that express a Camk2a-driven tet transactivator
transgene have been described previously and are congenic on a
129S6 genetic background [19,26]. The TRE-tauwt construct was
identical to that used to construct Tg(tauP301L)4510 mice except
for the presence of a wild type proline codon at position 301. The
rTg(tauwt)21221 line expressed human tau at levels comparable to
rTg(tauP301L)4510 [21]. All rTg mice and their controls, which
expressed either the CK-tTA or TRE-tau transgene alone, were
genetically homogeneous (FVB 6129)F1 hybrid mice.
Mapt
tm1(GFP)Klt Tg(MAPT)8cPdav/J mice, referred to as 8c
Mapt
0/0, have a targeted disruption of mouse Mapt exon one and
express a complete human MAPT transgene. They have been
described previously [27,28]. Breeder pairs of mixed genetic
background were obtained from the Jackson Laboratory. For these
experiments, we bred out the 8c human tau transgene to produce
mice lacking endogenous mouse tau. These mixed background
Mapt
0/0 mice were mated with Tg(tauwt), Tg(tauP301L), or Tg(CK-
tTA) mice. Mice hemizygous for activator or responder transgenes
and heterozygous for endogenous Mapt were backcrossed to the
Mapt
0/0 line to produce Tg(tauwt) Mapt
0/0, Tg(tauP301L) Mapt
0/0,
and Tg(CK-tTA) Mapt
0/0 mouse lines on mixed genetic back-
grounds that were used to produce Mapt
0/0 rTg mice with both the
responder and transactivator transgenes.
Ethics Statement
The studies at McLaughlin Research Institute (MRI), which is
fully accredited by AAALAC International, were carried out in
accordance with the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health, U.S. Public Health
Service. MRI’s Animal Assurance number from the Office of
Laboratory Welfare of the National Institutes of Health is A3901–
01. All procedures involving animals were reviewed and approved
by MRI’s Institutional Animal Care and Use committee under
protocol GAC-05. Fetuses were harvested from timed pregnant
females euthanized by cervical dislocation performed by trained
personnel.
Generation, Maintenance, and Differentiation of
Neurosphere Lines
TRE-tauwt or TRE-tauP301L females were mated with Tg(CK-
tTA) males. Neurospheres were isolated from whole brains from
individual E14 fetuses using established protocols described
previously [22,29]. The cells were grown in serum-free ‘‘Com-
plete’’ NeuroCult NSC Proliferation Medium comprised of
NeuroCult NSC Basal Medium (Stem Cell Technologies (SCT))
supplemented with Proliferation Supplement (SCT), 20 ng/mL
rhEGF (SCT), and penicillin/streptomycin (GIBCO). The neuro-
sphere sex was determined by PCR genotyping for the X and Y
chromosome genes Smcx and Smcy [30]. For passage, neurospheres
were enzymatically dissociated to single cells using the Papain
Tissue Dissociation Kit as per the manufacturer’s instructions
(Worthington Biochemical Corporation). Dissociated cells were
seeded at a concentration of 10
5 cells/mL in 15 mLs ‘‘Complete’’
NeuroCult NSC medium (Stem Cell Technologies) and main-
tained in a humidified incubator at 37uCi n6 %O 2 and 6.8% CO2
(balance N2). Neurosphere lines were passaged every 5–7 days.
Time of passage was determined by neurosphere density and
media color change. Colorimetric cell proliferation assays (MTT)
to assess neurosphere growth rates were conducted according to
the manufacturer’s recommendations (Cell Growth Determination
Kit, Sigma).
For immunofluorescent analysis (IFA) or immunohistochemis-
try, undifferentiated single cells, 8610
4 cells/well, were plated on
fibronectin (Invitrogen) coated 24-well glass bottom plates
(Greiner) and placed in a humidified incubator at 37uCa t6 %
CO2 6% O2 overnight.
To induce differentiation, dissociated cells were plated on
laminin/poly-L-ornithine (15 mg/mL poly-L-ornithine and 5 mg/
mL laminin) 24-well coated glass plates at a density of
12610
4 cells/well in complete NeuroCult medium (SCT). After
overnight culture the growth factor-containing medium was
removed and 0.3 mmol retinoic acid was added every other day
for seven days. Between days 8–25, cells were fed with B27-
containing medium (Gibco) on alternate days. IFA was performed
on day 21 or day 25.
Immunoblots
Adult mouse hemibrains for Western blot analysis were
prepared as described previously [19]. Mouse brains or neuro-
spheres were homogenized in ice-cold buffer consisting of 10mM
Tris-HCl, 1mM EGTA, 0.8M NaCl, 10% sucrose, pH 7.4,
Complete Protease Inhibitor Cocktail (Roche), and Phosphatase
Inhibitor Cocktail II (Calbiochem). 20 mg protein equivalent from
adult brain homogenates, 3610
6 cells from neurosphere lysates, or
10 mL from a 10% embryonic brain homogenate were electro-
phoresed on 12% Bis-Tris gels (Invitrogen) and electro-blotted
onto PVDF membranes (Millipore). In some cases, neurosphere
samples were treated with phosphatase prior to running; protein
lysates were suspended in 0.5 mg/10 mL of NEBuffer 3 (New
England Biolabs) and incubated with 10U/mL of calf intestinal
phosphatase (CIP) (New England Biolabs) for 60 minutes at 37uC.
We used the following anti-tau antibodies: Tau13 at 1:5000
(Covance); Tau1 at 1:200 (Chemicon); CP13, AT8, PHF-1, and
DA9 (provided courtesy of Dr. Peter Davies) at 1:200. The
specificity of these antibodies is summarized in Table 1. Loading
and transfer control anti-GAPDH was used at 1:2000 (Chemicon).
Goat anti-mouse HRP-conjugated IgG (Biorad) secondary anti-
body was diluted 1:10,000. SuperSignal West Pico reagent (Pierce)
was used for membranes probed with Tau13, Tau1, PHF-1, and
DA9; the ECL Plus substrate (Amersham) was used for
membranes probed with phospho-tau antibodies CP13 and AT8
and to detect immunoreactivity. For both chemiluminesence
systems, membranes were incubated with substrate for 3 minutes.
Chemiluminescence was detected using a Biorad VersaDoc at 3–5
minute exposures. Tau levels were normalized to GAPDH levels
to correct for loading and transfer differences.
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For whole neurosphere IFA, neurospheres were fixed in 4%
phosphate buffered paraformaldehyde followed by 30% sucrose
and equilibrated at 4uC overnight. Fixed neurospheres were
placed in embedding medium (Sakura Tissue-Tek O.C.T.) and
snap frozen in liquid nitrogen. Neurospheres were sectioned at
215uC; 8 mm sections were adhered to SuperFrost Plus micro-
scope slides (Fisher) and stored at 220uC for later IFA.
Cryosectioned neurospheres were stained with the following
primary antibodies: rabbit anti-Nestin at 1:200 (Covance); mouse
anti-human Tau13 at 1:5000 (Covance); mouse anti-Tau46 at
1:600 (Cell Signaling). The secondary antibodies Alexa488-goat
anti-mouse and Alexa546-goat anti-rabbit were used at 1:1500
dilution (Molecular Probes).
For analysis of individual undifferentiated cells plated on
fibronectin substrate and differentiated cells plated on LPO
substrate, cells were fixed at 37uC in PIPES fixative (0.1 M
PIPES, 1.0 mM EGTA, 3mM MgSO4 and 3% PFA). Cells were
permeabilized in 0.3% Triton X-100, placed in blocking buffer
(5% normal goat serum, 5% glycerol, and 0.04% sodium azide in
PBS), then incubated in primary antibody. Primary antibodies
Tau13, Tau46, Tau1, CP13, AT8, PHF-1, and DA9 were used at
dilutions described above. Rabbit anti-b tubulin III at 1:2000
(Covance); chicken anti-MAP2 at 1:10,000 (Covance); and rabbit
anti-GFAP at 1:1000 (Chemicon) also were used. The following
secondary antibodies from Molecular Probes were diluted 1:1500:
goat anti-mouse Alexa Fluor 546; goat anti-mouse Alexa Fluor
488; goat anti-rabbit Alexa Fluor 546; goat anti-rabbit Alexa Fluor
488; goat anti-rabbit Alexa Fluor 647. The goat anti-chicken
Alexa Fluor 488 antibody was from Jackson ImmunoResearch,
Inc and used at 1:200. Cells were coverslipped with ProLong Gold
antifade reagent containing DAPI (Invitrogen). Images were
acquired with a Nikon Eclipse TE2000 microscope and analyzed
with MetaMorph software. The proportion of total cells expressing
human tau (Tau13 positive) was determined for each cell line.
Fluorescence intensity and area stained, the threshold parameters,
were based on Tg(CK-tTA) control cell fluorescence and
fluorescence of cells incubated only with secondary antibody. All
image acquisition and cell counts were conducted by an
experimenter blind to genotype.
Immunohistochemistry
Cryosectioned neurospheres were thawed overnight and the
Vector M.O.M. peroxidase immunodetection kit was used to
detect transgene expression (Vector Laboratories, Inc) per
manufacturers instructions. Neurospheres were probed with
Tau13 at a dilution of 1:5000.
Filopodia-Spine Counts
To determine filopodia-spines densities, total Map2 positive
neurite lengths were measured 21 or 25 days post-differentia-
tion; an individual not involved in this experiment assigned a
code to each slide so the experimenter was blind to genotype.
All Map2-positive projections were measured using MetaMorph
software and counted along the Map2 positive neurites;
projections .12 mm were called neurites and ,12 mm were
called filopodia-spines. The number of filopodia-spines/100 mm
was calculated. Between 75–100 total Map2 and TUJ-1 double
positive cells were counted from each cell line. The average
filopodia-spine density/cell was calculated for each cell line.
Statistical Analyses
Both ANOVA and paired t tests were performed using
StatView 5 for Macintosh (SAS Institute, Inc.) for the
determining significance levels for differences in tau expression
levels between rTg(tauwt) and rTg(tauP301L) neurosphere lines.
For paired analysis, individual rTg(tauwt) and rTg(tauP301L) were
paired within each experiment according to order of harvest
(line number); in two experiments the numbers of mutant and
wild type lines were not equal, reducing the number of samples
from 22 to 20. For the ANOVA, experiment and tau genotype
were independent variables with fraction human tau positive,
the dependent variable. For ANOVA of the effects of
differentiation on the fractions tau positive cells in rTg(tauP301L)
and rTg(tauwt) neurosphere lines, differentiation state and tau
genotype were the independent variables. Independent variables
for analysis of spine density were time post-differentiation and
genotype. Post-hoc Bonferroni/Dunn analysis was performed on
ANOVA results. Correlation coefficients for the relationship
between spine density and fluorescence intensity were calculated
using StatPlus.
Results
CK-tTA Driven TRE-tau Transgenes were Expressed in
Neurospheres and Fetal Mice
We previously generated a Tg(tauwt) transgenic line that
harbors human wild type 4R0N tau transgenes driven by the
same TRE as Tg(tauP301L). When crossed to Tg(CK-tTA) mice,
the resulting rTg(tauwt) mice express human wild type tau at
levels comparable to those in rTg(tauP301L) mice [21]. We refer
to mice and cultures that carried both responder and activator
transgenes as rTg, and refer to those that carried only the
activator or responder transgene as Tg(CK-tTA) or TRE-
tauP301L and TRE-tauwt controls. Activator and responder
Table 1. Antibodies: epitopes recognized and relative sizes of mutant and wild type human tau in neurospheres and mice.
Relative Size
Antibody E14 Mice Neurospheres 2.5-mo old mice
Tau13 (human residues 2–18) tauwt.tauP301L tauwt.tauP301L tauwt.tauP301L
CP13 (pSer
202) tauwt.tauP301L tauwt.tauP301L tauwt.tauP301L
AT8 (pSer
202/pThr
205) tauwt.tauP301L tauwt.tauP301L tauwt.tauP301L
PHF-1 (pSer
396/pSer
404) tauwt.tauP301L tauwt.tauP301L tauwt.tauP301L
Tau1 (non-phospho Ser
198/Ser
202) tauwt=tauP301L tauwt=tauP301L tauwt.tauP301L
Epitopes recognized by each antibody are shown in parentheses. The more slowly migrating, and hence higher apparent MW, band is to the left and separated from the
smaller, more quickly migrating tau species by the symbol ‘‘.’’. The ‘‘=’’ symbol indicates no difference in apparent size of the tau species.
doi:10.1371/journal.pone.0039328.t001
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transgenes; therefore one-fourth of all pups were expected to
contain both the activator and responder transgenes and express
the protein of interest.
Expression of Camk2a, the promoter driving tTA expression, is
largely restricted to forebrain neurons [31]. CK mRNA [32] and
CK-tTA-driven tauP301L expression [20] had been reported to be
absent in mice until postnatal day 3. In contrast, our Western blot
analysis showed CK-driven expression of human tauwt and human
tauP301L as early as embryonic day 12 (E12) (Figure 1A–C). This
verified transgene expression prior to E14, the developmental age
that neurospheres are harvested.
rTg(tauwt) and rTg(tauP301L) Neurospheres Expressed
Human Tau at Comparable Levels
Neurosphere cultures were generated from individual fetuses
from Tg(CK-tTA) 6 TRE-tauwt and Tg(CK-tTA) 6 TRE-
tauP301L matings, and were genotyped. All cultures grew as non-
adherent free-floating aggregates characteristic of neurospheres
(Figure 1D). Neurospheres were probed with antibody for nestin,
an intermediate filament protein expressed by CNS-SCs, and were
tested for human tau protein expression by IFA and Western blot
with the Tau13 antibody. Nearly all cells in neurospheres were
nestin-positive (Figure 1E–G) as previously reported for neuro-
spheres from other mouse strains (28). Neurospheres from
rTg(tauP301L) and rTg(tauwt) cultures contained cells that also
expressed human tau (Figure 1F–G), but Tg(CK-tTA) controls did
not (Figure 1E). Western blot analyses on neurosphere lysates
confirmed human tau expression in rTg(tauP301L) and rTg(tauwt)
neurospheres, and showed that, as in mice, transgenic human tau
was expressed at comparable levels in neurospheres derived from
each genotype (Figure 1H).
Figure 1. rTg(tauwt) and rTg(tauP301L) fetuses and neurospheres expressed transgene encoded human tau. (A–C) Brains were taken
from Tg(CK-tTA) 6 TRE-tau pups at E12 (A) E13 (B) and E14 (C) for WB analysis with the human specific anti-tau antibody, Tau13. We saw
immunoreactivity only in brain homogenates from pups that genotyped positive for both transgenes. None of the samples from pups with either the
transactivator or responder transgene alone or with neither transgene were immunoreactive with Tau13. (D–G) Neurosphere cultures generated from
E14 Tg(CK-tTA) 6Tg(tau) mouse litters grew as non-adherent neurospheres and expressed human tau. (D) Representative phase contrast image of
neurospheres in culture. (E–G) Fixed and cryosectioned neurospheres analyzed by fluorescence microscopy demonstrated that nearly all cells in
Tg(CK-tTA) (E), rTg(tauP301L) (F), and rTg(tauwt) (G) expressed the CNS-SC protein, nestin (green). rTg(tauP301L) (F) and rTg(tauwt) (G) neurospheres
contained cells that were strongly immunoreactive with Tau13 (red); control Tg(CK-tTA) (E) neurospheres did not. DAPI nuclear stain is blue in E–G.
(H) Western blot analysis from two independent rTg(tauwt) neurosphere cell lines (cultures 1 and 2) and two independent rTg(tauP301L) neurosphere
cell lines (cultures 3 and 4) showed comparable levels of human tau between genotypes. Tau13 immunoreactivity was normalized to GAPDH. The
normalized values indicated that human tau levels were comparable between genotypes. Lysates from cultures 1 and 2 were probed together on one
blot, and lysates from cultures 3 and 4 were probed together on another. Control samples expressing only endogenous mouse tau (Mapt
+/+), or
neither mouse nor human tau (Mapt
0/0) were included on each membrane; only one set is shown here for the sake of simplicity.
doi:10.1371/journal.pone.0039328.g001
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Neurospheres and Independent Neurosphere Lines
Individual neurospheres within a single cell line (derived from a
single fetal brain) varied in transgene expression. Cryosectioned
neurospheres stained with Tau13 indicated that transgene-
expressing cells were not preferentially located at the periphery
nor deep within most spheres (Figure 1F, G; 2G), but neurospheres
varied in transgene expression within a single culture. Some
neurospheres in a culture contained nearly 100% tau transgene
expressing cells, whereas other neurospheres from the same
culture contained few, if any, human tau-expressing cells
(Figure 2G).
We analyzed individual cells for human tau protein levels by
measuring Tau13 fluorescence intensity. At passages 3 and 6 we
dissociated, fixed, and immunostained neurospheres (Figure 2).
Total cell numbers were based on intermediate filament nestin and
nuclear DAPI stains. The fraction of cells that expressed human
tau was determined. A cell was considered positive for transgene
expression if its Tau13 fluorescence was greater than the
background fluorescence seen when incubated only with second-
ary antibody. Figure 2A and 2B show cells strongly positive with
Tau13 in rTg cultures. Figures 2C and 2D indicate cells with very
low level expression of human tau in TRE cultures carrying the
responder transgene, but lacking the transactivator transgene; such
minimally reactive cells were not seen in cultures positive only for
the transactivator transgene (Figure 2E and 2H).
Cell lines generated from rTg(tauwt) fetuses contained a higher
proportion of cells expressing human tau than cultures harvested
from rTg(tauP301L) fetuses (Figure 3A). This was consistent among
four independent experiments (p,0.0001 ANOVA). Each exper-
iment was comprised of 2–4 independent rTg cell lines each
produced from an individual fetus in litters harvested at the same
time from Tg(CK-tTA) 6 TRE-tauwt and Tg(CK-tTA) 6 TRE-
tauP301L matings. The percentages of cells expressing tauP301L was
less in each experiment than the percentages of cells expressing
tauwt, though comparison of lines derived from fetuses harvested at
different times showed some overlap between mutant and wild
type lines. The fraction of positive cells within each culture
persisted over passage.
To further assess effects of mutant and wild type human tau on
the fraction of tau positive cells, we generated neurospheres from
three additional transgenic mouse lines that express the same
human tau variants as rTg(tauP301L)4510 and rTg(tauwt)21221, but
at lower levels as assessed by immunoblotting. In a single
experiment, we determined the percent of human tau expressing
cells present in neurosphere cultures produced from the additional
mouse lines. rTg(tauwt)14238 and rTg(tauP301L)14718 mice both
express human tau at ,50% the level of rTg(tauP301L)4510 and
rTg(tauwt)21221. The single neurosphere culture derived from a
rTg(tauwt)14238 fetus expressed human tau in 42.5% of its cells,
while the three neurosphere cultures derived from
rTg(tauP301L)14718 fetuses had 46%, 45%, and 71% expressing
cells. The third transgenic mouse line, rTg(tauP301L)14319,
expressed human tau at approximately 75% the level of
rTg(tauP301L)4510 and expressed human tau in ,60% of its cells.
In general, the proportions of cells expressing human tau in the
additional lines were within the range seen in the larger series of
experiments and reinforce the observation that the proportion of
cells expressing tau in an individual line is not necessarily
predictive of human tau genotype.
To determine the profile of Tau13 fluorescence intensity of
transgene expression, transgene-positive cells were binned (1 to
.10) based on fluorescence intensity (Figure 3B). The ‘‘dim’’ cells
indicated by the open arrows in Figure 2C and 2D fall in bin 1,
while the bright cells in Figure 2A and 2B are in bins 6 to .10.
Fluorescence intensity histograms are shown for three independent
rTg(tauwt) cultures (Figure 3B) and for three independent
rTg(tauP301L) cultures (Figure 3C) taken from one experiment
(Experiment 3 from Figure 3A). While the rTg(tauP301L) cultures
had a lower proportion of total cells expressing human tau
(Figure 3A), they contained a greater proportion of cells that
expressed higher levels of tau (brighter fluorescence intensity)
(Figure 3C) than rTg(tauwt) cells (Figure 3B). The TRE cultures,
which expressed the responder transgene alone, contained a
fraction of cells, approximately 41% of Tg(tauP301L) cells and 19%
of Tg(tauwt) cells that expressed human tau at very low levels
consistent with the leaky expression reported previously [19,33].
Tau Phosphorylation in Neurospheres
A characteristic of both tauopathy patients and the
rTg(tauP301L)4510 FTD mouse model is tau misprocessing,
primarily phosphorylation. To determine if mutant tau-specific
phosphorylation occurred in neurospheres, we used a battery of
phospho-tau specific antibodies. Due to the numerous sites for
phosphorylation and other posttranslational modifications of the
tau protein, immunoblotted tau most often does not resolve as
distinct bands but instead as a heterogeneous protein smear. To
discriminate distinct tau species within the total tau population, we
used antibodies specific to total tau (DA9), human tau (Tau13),
and phospho-tau epitopes (CP13, AT8, PHF-1, Tau1; see Table 1
for epitope specificity). Each antibody was probed on independent
membranes simultaneous with GAPDH; the GAPDH blot
presented in Figure 4 is from the Tau1 blot. Complete blots for
each antibody are shown in Figures S1, S2, S3.
Immunoblotting with DA9 allowed us to determine total tau
(mouse and human) expression and visualize the electrophoretic
migration pattern of tau from both species (Figure 4A.) Densito-
metric analysis with DA9 indicated that rTg neurospheres
expressed over five-times the amount of total (mouse and human)
tau protein than Tg(CK-tTA) control samples that only express
mouse tau. The migration profile revealed by DA9 showed a
distinct band migrating at ,52 kDa only in cultures that expressed
mouse tau. This band was absent in non-transgene expressing
control samples from Mapt
0/0 neurospheres indicating that it was
3R mouse tau, the only tau isoform expressed in mice during
development [34]. Compared to non-transgene expressing con-
trols (shown here: Tg(CK-tTA) and TRE-tauP301L), rTg samples
had additional DA9 signals that appeared as a dense series of
diffuse bands up to ,60 kDa in rTg(tauwt) samples and ,58 kDa
in rTg(tauP301L) samples. Strikingly, the diffuse band in tauwt-
expressing samples had a slower migrating component than
tauP301L-expressing neurospheres. The slower migration of tauwt
also was revealed by DA9, Tau13, CP13, AT8, and PHF-1
antibodies (Figure 4A), possibly suggesting that wild type, rather
than P310L mutant, tau was hyperphosphorylated. Immunostain-
ing with an additional antibody, MC6, which is specific for
pSer235, demonstrated that wt tau is more heavily phosphorylated
at this epitope than P301L mutant tau; these results are presented
in Figure S4.
To better characterize the tau species within the diffuse bands
and the nature of the slower migrating tauwt band, we used
human-specific Tau13, phospho-tau specific antibodies, and
alkaline phosphatase treatment. The diffuse series of bands in
rTg samples and the slower migrating tauwt species were observed
with the Tau13 antibody confirming that they contained
transgene-encoded human tau. All tau transgene-negative control
samples lacked Tau13 signal confirming its specificity for human
tau. We analyzed the neurosphere lysates for phosphorylated tau
Frontotemporal Dementia Neurospheres
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tau immunoreactivity in Tg(CK-tTA) and TRE-tauP301L control
samples indicated endogenous mouse tau and appeared as distinct
52 and 53 kDa bands (Figure 4A). Human transgene expressing
samples with mouse tau contained the 52 and 53 kDa bands with
an additional protein smear up to ,60 kDa in rTg(tauwt) samples
and to ,58 kDa in rTg(tauP301L) samples indicative of phosphor-
ylated human tau. Strikingly, the more slowly migrating tauwt
band became more apparent with the phospho-tau antibodies
providing evidence that it was a phosphorylated tau species.
Densitometric normalization to GAPDH, showed that rTg
samples had greater immunoreactivity to CP13 (2.9x), AT8
(1.9x), and PHF1 (2.4x) than controls without human tau
transgenes.
Tau1 immunoreactivity and alkaline phosphatase treatment
confirmed that the migration difference between tauwt and
tauP301L was due to phosphorylation. The Tau1 antibody
recognizes tau species that are not phosphorylated at or near
Ser
198/202, and has decreased immunoreactivity when tau is
phosphorylated at these epitopes. Both tauwt and tauP301L-
expressing cultures contained Tau1-immunoreactive non-phos-
phorylated tau with identical banding patterns migrating at ,53
and 52 kDa (Figure 4A). TRE and Tg(CK-tTA) samples displayed
only the 52 kDa band with Tau1 representing non-phosphorylat-
ed mouse tau. We treated lysates with calf intestinal phosphatase
(CIP); to restrict analysis to human tau only, we analyzed
neurosphere lysates from tauwt and tauP301L expressing cultures
on the Mapt
0/0 background lacking endogenous mouse tau
expression. Phosphatase treatment abolished the higher molecular
weight bands (.52 kDa) providing evidence that they were
phosphorylated human tau. Only a single tau band migrating at
,52kDa, the known molecular weight of recombinant human tau
4R0N [35], remained after phosphatase treatment in both mutant
and wild type samples (Figure 4B). Collectively, these data
indicated that the difference between mutant and wild type tau
protein migration was due to phosphorylation, and not other post-
translational modifications. We did not recover sarkosyl insoluble
tau indicating that insoluble tau aggregates did not form in
undifferentiated cultures of either genotype indicating that tau
hyperphosphorylation at tauopathy-associated epitopes such as
those recognized by AT8 and PHF1 does not necessarily lead to
tau aggregation (data not shown).
Mapt
0/0 cultures have not been fully characterized. Here we
used them to help distinguish between mouse and human tau
bands. The wt3 rTg(tauwt) Mapt
0/0 culture with low total tau (DA9)
and human tau (Tau13) immunoreactivity may be due to the low
proportion of human tau expressing cells (42%) compared to the
other rTg(tauwt) Mapt
0/0 culture, wt4 with 62% tau-expressing
cells.
Brain homogenates from E14, the developmental stage at which
neurospheres were harvested, and young adult 2.5 month-old mice
were analyzed for tau phosphorylation. As seen in neurospheres,
rTg(tauwt) brain homogenates displayed a distinctly slower
migrating tau species than rTg(tauP301L) (Figure 4C) demonstrat-
ing that neurospheres reliably model the difference between wild
type and mutant tau phosphorylation that is seen in vivo. Of note, a
lower molecular weight mouse tau isoform that stained intensely
with phospho-tau antibodies in E14 brains was absent in 2.5-
month-old mice. During embryonic development, the vast
majority of tau is the lower molecular weight 3R tau isoform
(,48 kDa without posttranslational modifications) [34] that is
heavily phosphorylated [36,37]. By postnatal day 24, fetal tau
isoforms have been replaced with larger, though less phosphor-
ylated, tau isoforms [34,38]. The lower molecular weight tau
species unique to E14 brains likely represents heavily phosphor-
ylated fetal mouse tau. Also of note, adult rTg(tauwt) mice
contained a higher molecular weight Tau1-immunoreactive tau
species than adult rTg(tauP301L), suggesting that young adult
rTg(tauwt) mice express a tau species not phosphorylated at Ser
198/
202 that is either more heavily phosphorylated at other epitope(s),
or has other post-translational modifications distinct from tauP301L.
Results from these analyses are summarized in Table 1.
We assessed tau phosphorylation in dispersed cells from
dissociated neurospheres. For each cell culture we determined
the proportion of nestin stained cells that also were immunore-
active with phospho-tau antibodies. rTg cultures contained a
greater proportion of cells immunoreactive to phospho-tau
antibodies than Tg(CK-tTA) controls. The AT8 antibody revealed
focal staining in nuclei of all genotypes expressing mouse tau
(Figure 5). The staining was absent in Mapt
0/0 cells and likely
represents binding of 3R pSer
202/Thr
205 mouse tau to nucleolar
organizing regions in dividing cells as reported previously [39–41].
This staining was not observed with CP13, which recognizes a
different epitope associated with pSer
202, nor in non-dividing cells
after differentiation. The presence of appropriately phosphorylat-
ed nucleolar mouse tau in dividing, but not differentiated cells,
indicates that overexpression of human tau did not compromise
physiological tau modification and function.
Stem or Progenitor Cell Populations that Express Human
Tau Transgenes Maintained Stem Cell Properties
We examined the variability of self-renewal and differentiation
among independent cell lines. Although there was an effect of the
P301L mutation on tau phosphorylation, expression of mutant or
wild type human tau did not obviously interfere with their SC
properties. Human tau expression did not alter the proliferation
rate of neurosphere lines; regardless of genotype, all cell lines
required passaging every 5–7 days. We conducted quantitative cell
proliferation assays between passages 2–3 and between passages 6–
7 on cell lines of all genotypes. Independent cultures of all
genotypes had similar doubling times ranging from 20 to 32 hours
as previously reported for neural SC lines [42]. TauP301L-
expressing cultures had a shorter, though non-significant, doubling
time of 23.364 hours (n=3), than controls and rTg(tauwt) with
29.468.8 hours (n=5) and 29.365.5 hours (n=3) doubling times.
Figure 2. Single-cell staining revealed protein expression heterogeneity in transgene expressing cells. Nestin staining is shown in
green (A through F), Tau13 (A through E) or Tau46 (F) in red, and DAPI in blue (A through F). A proportion of cells from rTg(tauwt) (21–30%) (A) and
rTg(tauP301L) (38–44%) (B) cultures displayed strong immunoreactivity with Tau13 (solid arrow), while others had weak immunoreactivity with Tau13
(open arrow). Cultures containing responder transgene alone, TRE-tauwt (C) and TRE-tauP301L (D), did not contain any cells with strong Tau13
immunoreactivity, but they did contain some cells with weak immunoreactivity (open arrows) indicative of leaky transgene expression. (E) Cultures
containing only the transactivator transgene, Tg(CK-tTA), did not express human tau but were immunoreactive with Tau46 (F), an anti-tau antibody
that reacts with both mouse and human tau. Nearly all cells of all genotypes were immunoreactive with the anti-nestin antibody (green). Scale bar
=25mm. (G) Immunohistochemistry of cryosectioned neurospheres probed with Tau13 revealed that some neurospheres from rTg cultures,
rTg(tauP301L) shown here, contained a large proportion of transgene expressing cells (closed arrow), other neurospheres from the same culture
contained very few transgene expressing cells (open arrow). (H) Control Tg(CK-tTA) neurospheres were not immunoreactive with Tau13.
doi:10.1371/journal.pone.0039328.g002
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expression or growth rates.
To investigate effects of transgene expression on neurosphere
multipotency and differentiation, we plated dissociated neuro-
sphere cells on laminin/poly-L-ornithine coated glass bottomed
plates in basal medium supplemented with retinoic acid [43,44].
After 21 or 25 days, we fixed, stained, and visualized the cells with
IFA using antibodies against neuronal and glial antigens.
Differentiated rTg(tauP301L), rTg(tauwt), and Tg(CK-tTA) control
neurospheres all contained cells positive for neuronal proteins
microtubule associated protein 2 (recognized by Map2 antibody)
and b-tubulin III (recognized by TUJ-1 antibody) or the astrocytic
protein, glial fibrillary acidic protein (GFAP) (Figure 6). Though
mature neurons restrict Map2 expression to dendritic spines,
immature neurons express Map2 in developing axons as well as in
developing dendrites [45–48]. Neuritic projections contained both
b-tubulin III and Map2 expression, but in contrast to the smooth
axonal TUJ-1 staining, Map2 staining had a spiny morphology
indicative of developing dendritic-spines (Figure 6).
The rTg cell lines contained cells that co-expressed neuronal
proteins and human tau and cells that co-expressed GFAP and
human tau (Figure 6A, B). All genotypes contained similar
proportions of cells immunoreactive with both Map2 and TUJ-
1, 3–5%, indicating that transgene expression did not alter
neuronal cell differentiation. Compared to tauwt-expressing
cultures, tauP301L cultures contained fewer neuronal protein
expressing cells that also expressed human tau; the proportions
mirrored that of undifferentiated cells co-expressing nestin and
human tau (Figure 7).
We observed a difference in filopodia-spine density between
rTg(tauP301L) and rTg(tauwt) differentiated cells at 25 days after
exposure to differentiation stimuli. Mature dendritic spines
develop from elongated filopodial projections [49–53]. Here we
counted the density of these dendritic spine precursors, filopodia-
spines, from differentiated cells derived from neurosphere cultures.
The filopodia-spine density among genotypes did not differ
significantly at 21 days post-differentiation, but became statistically
significant 4 days later (Figure 8B). The filopodia-spine density
increased between days 21 and 25 in tauP301L cultures; conversely,
the filopodia-spine density in the tauwt and control cultures slightly
decreased during this interval. At 25 days post-differentiation, cells
derived from tauP301L-expressing neurospheres had a 2363%
higher filopodia-spine density than neurons derived from tauwt-
expressing cultures, and 20+/24% higher filopodia-spine density
than non-Tg expressing controls (p,0.0001); rTg(tauP301L) Mapt
0/
0 and rTg(tauwt) Mapt
0/0 cultures showed similar results (data not
shown). Interestingly, we saw an association with cell culture
genotype, but not with the level of transgene expression in
individual cells, with spine density. Within a single culture, cells
expressing high levels of human tau had filopodia-spine densities
similar to those in cells expressing low levels of human tau and
cells in which transgene-encoded protein was not detectable
(Figure 8C). We did not observe any genotype-specific differences
in tau localization to spines in differentiated cells (Figure 8A);
transgene-positive tauwt and tauP301L cells expressed human tau
throughout their neuritic projections.
In addition to cell types with antigen expression and morphol-
ogy characteristic of neurons or astrocytes, a population of very
large cells that, in some cases, had a diameter over 100 mm
emerged. These cells had a flattened appearance, some were
Figure 3. rTg(tauwt) neurospheres contain more human tau
expressing cells than rTg(tauP301L) neurospheres. Undifferenti-
ated single cells (shown in Figure 2) stained with DAPI and nestin were
counted and the proportion co-expressing Tau13 was determined. (A)
Consistently the proportion of cells co-expressing Tau13 was signifi-
cantly higher in rTg(tauwt) cultures than rTg(tauP301L) cultures. Four
independent experiments consisting of 11 independent rTg(tauwt)
cultures and 11 independent rTg(tauP301L) cultures are shown here
(ANOVA: variation due to experiment F =5.5, P=.01; ANOVA mutant
versus wild type F =65.9, P,0.0001. Interaction between experiment
and tau genotype was marginally significant: F =3.8, P =0.035.)
Following Bonferonni/Dunn correction, the mutant versus wild type
comparison remained significant at P,0.0001. Paired t test also
indicated a significant difference between rTg(tauP301L) and rTg(tauwt)
neurospheres (P,0.0001). Closed circles represent tauwt; open circles
represent tauP301L. (B, C) Fluorescence intensity histograms from
Figure 3A’s Experiment 3 cells revealed heterogeneity in transgene
expressing cells. Transgene positive cells were binned (1 to .10) based
on fluorescence intensity. ‘‘1’’ indicates a ‘‘dim’’ cell with low transgene
expression (open arrow from Figure 2), and bins 6 through .10
indicated ‘‘bright’’ cells with high transgene expression (closed arrow
from Figure 2); proportion of cells is on the y-axis. The left-skewed
rTg(tauwt) histogram (B) indicated that most Tau13-positive cells
expressed human tau at low levels. In contrast, the bimodal
rTg(tauP301L) histogram indicated two distinct cell populations: one
comparable to rTg(tauwt) and one with higher transgene expression
levels. TRE cell lines, TRE-tauP301L in this experiment, expressed human
tau at low levels; all cells fell in bins 1 and 2.
doi:10.1371/journal.pone.0039328.g003
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not Map2, b-tubulin III, or GABA; some expressed human tau.
These cells first appeared in culture ,7 days after induction of
differentiation and grew in size until the cultures reached
confluence. Examples of these cells can be seen in Figure 6. They
appeared after growth factor withdrawal upon receiving differen-
tiation stimuli and developed morphological phenotypes resem-
bling senescent cells [54] and may indicate cells that did not
receive the appropriate stimuli to complete differentiation and
remained in a pseudo-stem cell state. While morphologically and
antigenically distinct neural precursor cells have been identified in
neurospheres, one of which is EGF-responsive and the other
morphologically large EGF/FGF-2 responsive cells [55], we did
not supplement cultures with FGF-2. Though neurospheres may
have endogenously synthesized FGF-2 [25], the uncharacterized
cells did not display strong nestin immunoreactivity typical of
neural SCs.
Discussion
The impetus for these studies was to use a well-characterized
mouse model for frontotemporal dementia to assess whether CNS-
SC cultures reproduced genetic differences seen in the mice from
which they were derived and whether independent isolates from
genetically identical hosts produced consistent phenotypes. Neuro-
spheres derived from tauwt–expressing mice contained more
heavily phosphorylated tau species with slower electrophoretic
motility than tauP301L. The phosphorylation differences between
tauP301L and tauwt also occurred in fetal mouse brains and
persisted through young adulthood. Though hyperphosphorylated
tau is considered a hallmark feature of tauopathy, several disease-
causing mutant tau variants actually are less phosphorylated than
tauwt in vitro [56–59] and in young mice [60–62]. While
abnormally phosphorylated tau in aged rTg(tauP301L)4510 mice
coincides with memory and behavioral abnormalities [20,60], the
hypophosphorylated tauP301L seen in young mice may have pre-
clinical significance and deserves attention. Transgenic mice that
express pseudohyperphosphorylated tau, an engineered tau
variant that mimics constitutively phosphorylated tau by replacing
Ser/Thr residues with glutamate [63], did not develop tau
aggregates, neuronal loss, or behavioral abnormalities [64]. In
contrast, mice expressing tauR406W, a variant that remains
hypophosphorylated compared to tauwt even in aged mice,
developed age-dependent tau aggregates [65] and memory and
behavioral abnormalities [66].
Figure 4. Transgene-encoded human tauwt is more heavily
phosphorylated than tauP301L. (A) Electrophoresed and blotted
neurosphere lysates were probed with antibodies against total tau
(mouse and human): DA9; human tau: Tau13; phospho-tau: CP13, AT8,
and PHF-1; and non-phospho tau: Tau1. In control samples, TRE
(tauP301L shown here) and Tg(CK-tTA), all antibodies, except Tau13,
revealed a mouse tau band at ,52kDa that is absent from Mapt
0/0
samples. Human tau from rTg samples migrated as a diffuse series of
bands indicative of a heterogenous population of tau species. Human
tauwt-expressing cells contained more slowly migrating tau species
(,53 to 60 kDa) than tauP301L-expressing cells (,53 to 58 kDa) with all
anti-tau antibodies, except Tau1, indicating a more heavily phosphor-
ylated tau species in rTg(tauwt) than rTg(tauP301L). Tau1 probed samples
revealed an identical migration pattern with both rTg genotypes. In all
blots, MW lines indicate 60, 58, 53, 52 kDa, respectively. All samples
probed with the each tau antibody were blotted on the same
membrane. GAPDH was probed simultaneously with each tau antibody;
the example of GAPDH immunostaining shown is taken from the Tau1
blot. Mapt
0/0 and control samples were run on each blot but rearranged
in the figure for presentation purposes. See Figures S1 for the original
blots for each antibody showing the Mapt
0/0 and control samples in
their locations before rearrangement for presentation, along with
GAPDH immunostaining for each blot. (B) Tau protein from rTg(tauwt)
Mapt
0/0 and rTg(tauP301L) Mapt
0/0 neurosphere lysates had the same
electrophoretic mobility after phosphatase treatment. Untreated
samples (-) showed the characteristic slower migrating (,60 kDa)
trailing edge for tauwt compared to tauP301L. Calf-intestinal phosphatase
(CIP) treatment (+) abolished the higher molecular weight phospho-tau
bands (.52 kDa) leaving a single tau band migrating at ,52kDa in
both rTg genotypes. (C) Human tau from rTg(tauwt) E14 and adult mice
contained more slowly migrating phospho-tau species than
rTg(tauP301L) as seen in neurospheres. No immunoreactivity was
observed in Mapt
0/0 samples with any anti-tau antibody; * = mouse
tau. All samples probed with each tau antibody were blotted on the
same membrane. GAPDH was probed simultaneously with each tau
antibody; the example of GAPDH immunostaining shown is taken from
the AT8 blot. Mapt
0/0 and control samples were run on each blot but
rearranged in the figure for presentation purposes. See Figures S2 and
S3 for complete, un-rearranged blots showing all samples that were
run.
doi:10.1371/journal.pone.0039328.g004
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39328The hypophosphorylated tauP301L species in neurospheres and
young mice may represent free tau not associated with microtu-
bules (MT). Tau bound to MTs acquires more phosphorylation
than free tau as demonstrated by in vitro phosphorylation of tau in
the presence or absence of MTs [59,67]. Many of the MAPT exon
10 missense mutations that cause dementia, including P301L,
reduce the ability of tau to interact with MT [68–71], and tauwt
displaces mutant tau from MTs [63,72]. The absence of tauP301L
aggregates or neurofibrillary tangles (NFTs) in neurospheres and
in young mice, despite phosphorylation at many of the sites most
frequently phosphorylated in AD and FTD (pSer
202, pSer
396,
pSer
235, pSer
404) [36,73–76], also may correspond to unbound tau
as MT association has been implicated as an important step for tau
nucleation [77,78]. The quantity of NFTs correlates with disease
severity [79]. However, recent studies have dissociated NFTs from
neuronal death [80–82] and decreased memory function [19], and
instead suggest a deleterious effect of soluble tau.
Phosphorylation of mouse tau also reflects appropriate phos-
phorylation corresponding to the differentiation state. Heavily
phosphorylated 3R mouse tau is know to bind to nucleolar
organizing regions in dividing cells [39–41] and was also observed
in neurospheres, indicating that human tau did not inhibit either
the cellular machinery or kinases involved. This reinforces the
same conclusion coming from the recapitulation of the genetic
differences in human tau phosphorylation seen in neurosphere
culture.
Figure 5. Overexpression of human tau did not interfere with localization of mouse tau to the nucleus in undifferentiated dividing
cells. IFA revealed a punctate nuclear tau species (arrow) immunoreactive to AT8 (A) but not CP13 (B) in dissociated undifferentiated neurospheres.
AT8 immunoreactivity, indicative of pSer
202/Thr
205 tau, was seen in the nucleus of all genotypes that expressed mouse tau, but was absent in cultures
derived from Mapt
0/0 or in differentiated cells providing evidenced that it was of mouse origin and corresponded to actively dividing cells but not
mature cell types.
doi:10.1371/journal.pone.0039328.g005
Figure 6. Dissociated neurospheres stimulated with retinoic acid differentiated into cells that expressed neuronal or glial antigens.
Each rTg(tauP301L) (panel A) and rTg(tauwt) (panel B) culture contained cells positive for Tau13 and TUJ-1, Tau13 and Map2, and Tau13 and GFAP;
merged images of Tau13 (red) with TUJ-1, Map2, or GFAP (green) are presented; yellow color indicates overlapping expression. Tg(CK-tTA) control
cells are shown in panel C. Arrows point to spiny projections labeled with Map2 staining. Scale bar =10 mm. Cells were simultaneously stained with
three different secondary antibodies (Alexa 546 a-mouse for Tau13; Alexa 647 a-rabbit for TUJ-1; Alexa 488 a-chicken for Map2) and each fluorophore
was imaged in separate channels. Alexa 546 was artificially colored red, and Alexa 647 and 488 were both artificially colored green for color-combine
with Tau13.
doi:10.1371/journal.pone.0039328.g006
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tauwt and tauP301L differentiated cells. Developmentally, dendritic
spine morphology evolves from long thin filopodia-spines to
mature spines of various morphologies; during this transformation,
filopodia-spine density decreases [49–53]. We observed a slightly
higher filopodia-spine density in Map2 and TUJ-1 double-positive
cells from tauP301L cultures than those derived from tauwt or
cultures that did not express MAPT. While the level of transgene
expression within individual cells did not affect filopodia-spine
density, we have not ruled out an effect of the transgene insertion
site. Interestingly, in a separate P301L mouse line that that
harbors the mutation in the longest mouse tau isoform, 4R2N,
driven by the Thy1 promoter, young mice with ‘‘hypopho-
sphorylated’’ tau have enhanced learning and memory and
increased Long Term Potentiation (LTP) in the dentate gyrus
compared to controls [61]. With age, the spine density of
rTg(tauP301L)4510 mice decreases and coincides with increased
neuronal excitability [81]. Whether or not the greater filopodia-
spine density we observed in differentiated tauP301L cultures relates
to enhanced LTP in young mice or neuronal vulnerability later in
life in unknown, but warrants further exploration.
We did not observe mislocalization of tauP301L to dendritic
spines, as reported in aging mice [60] or in transfected rat neuron
cultures [21]. We saw high levels of transgenic tau protein
throughout neuritic projections in differentiated neurospheres
from both human tau transgene genotypes. The presence of tau in
the filopodia-spines of developing cells [74,83] suggests that the
phenomenon correlates with a dynamic morphology and does not
necessarily indicate pathological injury.
Overall, phenotypes of neurosphere cultures isolated from
individual fetuses at different times reflected the genotype of the
mice from which they were derived and proved highly similar in
transgene expression, proliferation, and differentiation. Unlike
clonal cultures, these neurospheres were formed by aggregation,
which results in culture heterogeneity [22–25]. During culture
they merge and fuse as well as proliferate [84,85], which likely
resulted in the heterogeneous composition of transgene expressing
and non-expressing cells within the same sphere. The minor
transgene expression variability among neurosphere cultures
generated from littermate fetuses possibly occurred during the
initial brain harvest. We did not specifically dissect the forebrain
from each fetus. Nestin expressing neural SCs in the developing
midbrain [86] and hindbrain [87] may have contributed to the
transgene expressing cell population since CKIIa, the promoter
driving tTA-transgenic human tau expression, is expressed
throughout the brain at this developmental age [88]. We saw
more variability among independent experimental harvests than
among cultures derived from littermate fetuses; we attribute this
variation to inconsistencies inherent to IFA. Regardless, IFA
consistently demonstrated that undifferentiated cells derived from
rTg(tauwt) expressing fetal brains expressed human tau in a higher
proportion of cells than those derived from rTg(tauP301L)
expressing fetal brains.
Total brain homogenates indicate that rTg(tauwt) mice express
comparable levels of transgenic tau as rTg(tauP301L) [21]. While
the rTg(tauP301L) cultures had a lower proportion of total cells
expressing human tau, they contained a greater proportion of cells
that expressed higher levels of tau (brighter fluorescence intensity).
This feature of some transgenes is caused by position-effect
variegation [89–91]. Neurospheres, like the mice from which they
were derived, may show this effect and could be useful models for
screening transgene expression in founder lines. Consistent with
the difference in transgene expression seen in undifferentiated
neurospheres, differentiated cells derived from tauwt-expressing
neurospheres expressed human tau in a higher proportion of cells
than those derived from tauP301L-expressing neurospheres. Likely,
non-transgene expressing progenitor cells gave rise to non-
transgene expressing differentiated cells and transgene expressing
progenitor cells differentiated into transgene expressing mature
cells. Alternatively, tauP301L transgene expression may have
decreased neural precursor survival. Since neurospheres prolifer-
ated and differentiated over several passages in both genotypes,
and differentiated transgene expressing cell proportions mirrored
that of the undifferentiated condition, evidence favors the former
explanation.
Some of the differences we saw between tauP301L and tauwt may
stem from differences in transgene insertion sites. Neurosphere
cultures from mouse lines expressing the same human tau variants,
but at lower levels than rTg(tauP301L)4510 and rTg(tauwt)21221,
overlapped in the percentages of cells expressing human tau, but
within the same range as our more extensively studies lines. It is
likely that there are effects of transgene insertion site as well as the
tau mutation.
With the emergence of methodologies to culture neurospheres
from human patients [14], experiments evaluating the culture
system’s relevance and validity are crucial. Our data provide
supporting evidence that neurospheres can reliably model
phenotypes of their derived source over extended culture periods.
The neurosphere culture system provides a robust assay for
studying effects of external factors on the development and
differentiation of the CNS, and the genetic susceptibility to
neurological disorders. While it is unreasonable to expect that an
in vitro system will fully recapitulate a complex disease process
involving complex cell interactions, biologically relevant models
that provide reproducible results are invaluable resources. This SC
model shares the genetics of mice that model human FTD, and
has shown the capacity to model pre-disease, genotype-specific
phenotypes. By using mice expressing either of two distinct
transgenes as the source of SCs, we have established that
neurosphere cultures maintain genotype-specific characteristics.
Our results lend credence to the growing body of data
supporting the development and use of patient specific-stem cell
lines to study disease. We have already shown that these cells
reproducibly mimic biological events of the mice from which they
Figure 7. The proportion of differentiated cells that expressed
human tau reflected that of undifferentiated neurospheres.
Differentiated cells immunoreactive with both Map2 and TUJ-1
antibodies were counted; the proportion co-expressing Tau13 is
presented here. Presented are results from four independent rTg(tauwt)
cultures and three independent rTg(tauP301L) cultures generated from
two litters of each Tg(CK-tTA) 6TRE-tau mating. The four litters were
harvested, genotyped, and cultured simultaneous. They yielded four
rTg(tauwt) and three rTg(tauP301L) pups for neurosphere culture shown
here. By ANOVA, the proportions of differentiated cells (closed symbols)
did not differ from those of the neurospheres (open symbols) (ANOVA,
F=.008, P=.93). The different symbols represent individual cell lines
before and after differentiation. Genotype had a highly significant effect
even after Bonferroni correction (**: ANOVA, p,0.0001).
doi:10.1371/journal.pone.0039328.g007
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PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e39328Figure 8. rTg(tauP301L) cells developed more filopodia-spines than differentiated rTg(tauwt) and non-transgene expressing control
cells. (A) Cells differentiated for 21 or 25 days were evaluated for the number of Map2 positive filopodia-spines and tau localization. Shown here are
data pooled from three independent rTg(tauP301L) and four independent rTg(tauwt) lines. We observed transgenic tau expression, visualized by Tau13
immunoreactivity, throughout Map2 positive neurites and filopodia-spines in both tauP301L (top panel) and tauwt (bottom panel) expressing cells.
Arrows point to filopodia-spines. Scale bar =10 mm. (B) The density, filopodia-spines/100 mm, was plotted for each genotype (n indicates number of
cells counted). Time post-differentiation did not significantly affect spine density (ANOVA, F=1.2, P=.28), but there was a significant interaction
between genotype and time (F=6.5, P=0.0016) with spine density in rTg(tauP301L) neurospheres at 25 days significantly (**, P,.0001) greater than in
rTg(tauwt) or TgCKtTA neurospheres. Overall the effect of genotype was highly significant (ANOVA, F=13.3, P,0.001) The horizontal lines inside the
boxes demarcate the mean filopodia-spine densities, circles indicate outliers; ‘‘n’’ indicates number of cells counted. (c) Plotting of spine density
against fluorescence intensity revealed no correlation (R
2=0.01) between protein expression level and filopodia-spine density. Closed circles
represent rTg(tauwt) cells, open circles represent rTg(tauP301L) cells.
doi:10.1371/journal.pone.0039328.g008
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involved in tau modification genetically validating the utility of SC
as a model system. We are now in a position to interrogate the
system. We are focusing on microarray analysis experiments to
uncover differentially regulated genes between tauP301L and tauwt
mice and neurosphere cultures. Preliminary results are encourag-
ing and show consistency in genotype-specific gene expression
patterns among independently derived neurosphere lines. This will
direct hypotheses about potential pathways targeted in cells that
carry the tauP301L gene. By extending this research to patient-
specific SCs, high-throughput cell based genetic screening (cDNA
or siRNA) assays could uncover small molecules and potential
pathways involved in pathogenesis and, ideally, the genetic
specificity of the system may lead to treatment therapies tailored
to unique patient needs.
Supporting Information
Figure S1 Entire, unrearranged immunoblots used to
generate Figure 4. Figure 4 immunoblots were rearranged for
clarity of presentation and some lanes removed for uniform
presentation of our results. In this supporting figure, we present
entire blots with their respective GAPDH loading controls. (A)
Lane loading was identical for DA9 and Tau1 membranes as
shown. (B) The Tau13 blot was loaded in the same orientation as
DA9 and Tau1, but contained only the TREwt control. (C) Lane
arrangement was identical for CP13 and AT8 membranes. (D)
Lane arrangement for PHF-1. In Figure S1 A–D, DA9, Tau1,
Tau13, and PHF-1 membranes were blotted simultaneously with
GAPDH and the full membranes are shown. CP13 and AT8
antibodies required a more sensitive ECL system than the other
antibodies, requiring probing GAPDH independently after cutting
the blot; membrane reconstruction is shown. rTg(tau) sample
labels (i.e. wt1, P301L1,w t 2, P301L2, etc.) correspond to those
shown in Figure 4.
(TIF)
Figure S2 Original immunoblots used to generate
Figure 4C showing results from embryonic day 14 mice.
For simplicity, only one representative mouse for each genotype
was shown in Figure 4C; all samples are shown here. GAPDH was
probed simultaneously with each of the anti-tau antibodies; whole
immunoblots are shown.
(TIF)
Figure S3 Original 2.5-month-old mouse immunoblots
used to generate Figure 4C. For simplicity, only one
representative mouse for each genotype was shown in Figure 4C;
all samples are shown here. GAPDH was probed simultaneously
with each of the anti-tau antibodies; whole immunoblots are
shown.
(TIF)
Figure S4 rTg(tauwt) neurospheres were more heavily
phosphorylated at Ser
235 than rTg(tauP301L) neuro-
spheres. rTg(tauwt) and rTg(tauP301L) neurospheres, with or
without endogenous mouse tau, were immunoreactive with the
MC6 (anti-pSer
235) antibody. As seen with the other phospho-tau
antibodies, rTg(tauwt) neurospheres displayed a slower migrating
band than rTg(tauP301L) neurospheres. The membrane was
subsequently probed with Tau13; the characteristic migration
difference between tauwt and tauP301L–expressing samples was
apparent.
(TIF)
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